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Abstract 
The number of clinical trials for Duchenne muscular dystrophy is increasing. Many trials require muscle biopsies, which involve an 
invasive surgical procedure. Little is known about short- and long-term impacts of muscle biopsies as perceived by patients and caregivers. 
Therefore a survey was held among patients and their caregivers who participated in trials involving muscle biopsies, in seven countries. 
Seventy-eight responses were received. Analysis revealed that many patients and parents had significant anxiety before the biopsy. The main 
concern of caregivers was the required general anaesthesia. In most cases biopsies caused pain and temporarily hampered daily activities. The 
main long-term impact was scarring, although large variation in size was reported. Seventy-nine percent of caregivers were little bothered 
and 21% were moderately or severely bothered by the scar. Willingness to consider another biopsy in future protocols was higher for 
open-label studies than for placebo-controlled trials. Caregivers stressed the importance of knowing the results of biopsy analyses; only a 
minority actually received this information. Recommendations are made on the informed consent procedure regarding risks and consequences 
of muscle biopsies, and communication of results. Furthermore, efforts should be made to minimise the impact of biopsies through pain 
management and by considering plastic surgery. 
© 2019 The Authors. Published by Elsevier B.V. 
This is an open access article under the CC BY license. ( http://creativecommons.org/licenses/by/4.0/ ) 
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(. Introduction 
Duchenne muscular dystrophy (DMD) is a devastating
isorder hallmarked by progressive muscle weakness leading
o loss of ambulation in childhood, respiratory insufficiency,
ardiomyopathy and early death [1] . Mutations in the DMD
ene lead to absence of the dystrophin protein that normally
inks the extracellular matrix to the contractile elements in
he sarcolemma, which is thought to protect skeletal muscle∗ Corresponding author. 
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Please cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Mus
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nbres from contraction induced damage [2] . Muscle pathology
onsists of inflammation, failed muscle regeneration and a
rogressive replacement of muscle by fibrotic tissue and
at [3] . In order to stop these irreversible processes, a
umber of therapeutic strategies have been developed that
im to restore some form of dystrophin production or slow
own the pathological processes that lead to loss of muscle
issue. These include stop codon read-through compounds 
hat allow the production of low levels of dystrophin in
atients with nonsense mutations in dystrophin, various
ypes of antisense oligonucleotides (AON) that allow the
roduction of partially functional dystrophins by restoring thess article under the CC BY license. 
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a  disrupted reading frame through exon skipping of pre-mRNA
transcripts, and delivery of micro-dystrophins using adeno-
associated viral vectors. Other therapeutic approaches aim to
increase levels of utrophin, a protein with similar properties
as dystrophin, to reduce the levels of myostatin, an inhibitor
of muscle growth, in order to increase muscle mass, or to
use histone deacetylase (HDAC) inhibitors to simultaneously
boost muscle regenerative capacity, and reduce inflammation
and fibrosis formation [4] . 
Over the past 12 years, these compounds have been tested
in clinical trials, which involved muscle biopsies of various
muscles as defined by the study protocol of that trial [5–18] .
While invasive, the biopsies were taken to obtain evidence
that the compound was performing as proposed, i.e. showing
dystrophin expression for dystrophin restoring approaches,
increased utrophin levels for utrophin upregulating
approaches, or reducing levels of fibrosis and inflammation
for HDAC-inhibitors [16] . Furthermore, in dose escalation
studies, biopsies were performed to discover the optimal dose
for the therapeutic compounds [6,9,12–14,16,18] . Finally, in
2016 the exon 51 skipping compound eteplirsen received
accelerated approval from the Food and Drug Administration
(FDA; USA) based on small increases in dystrophin in
muscle biopsies obtained from treated patients [19] . 
Given the invasive nature of muscle biopsies, stakeholders
in the DMD field including medical ethical boards throughout
the world have struggled with the balance between necessity
and burden of muscle biopsies performed in children. A
biopsy will cause some kind of pain during the healing
process, and will leave a permanent scar. In most cases,
general anaesthesia is required for which careful planning is
essential in this patient population. The extent of the scar is
influenced by the technique used. Needle and conchotome
biopsies can be done through relatively small incisions,
potentially even smaller than one centimetre, whereas open
biopsies require incisions of several centimetres, especially
in areas with more subcutaneous fat [20] . The conchotome
is a angled scissor-like device hat cuts muscle through
the opening and closing of a sharp-edged jaw [21] . While
smaller biopsies are obviously preferred, sometimes protocols
request larger, open biopsies, e.g. when more extensive
analyses are required, to obtain spare samples for validation
experiments, or to serve as backups in case of complex
logistic handling. Although the extent of the burden for
patients and families is crucial in the process of deciding
whether to participate in a trial involving muscle biopsies,
consistent data on short- and long-term effects of these
muscle biopsies are lacking [22] . To address this, the aim
of the current study was to learn the patients’ and caregivers’
perspectives on the burden of muscle biopsies obtained in
clinical trials. Furthermore, the hope was to identify ways to
attenuate the burden of the muscle biopsy procedure for future
trials. This effort was initiated by patient representatives
and performed in collaboration with academic researchers.
Jointly, a questionnaire was constructed, translated, and sent
to patients and caregivers who had participated in any relevant
clinical trial for DMD between 2007 and 2017. Please cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Mus
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.n. Materials and methods 
.1. Questionnaire 
The questionnaire was designed in English by four
embers of the muscle biopsy working group (AJ, AAR,
HN and FM). It consisted of three parts: 1) General
haracteristics of the patient, which clinical trial they had
articipated in, the number and location of the biopsies taken
s defined in the study protocol, and if general or local
naesthesia had been used; 2) Perception of the child about
he biopsy; 3) Perception of the parent/caregiver about the
iopsy. It consisted of a combination of multiple choice
uestions, scales, and open questions. The questionnaire
ddressed both short-term and long-term impacts, as well as
eneral concerns and recommendations for future trials. It
as made clear that responses had to be focused on biopsies
erformed as part of a clinical trial, and not of any diagnostic
rocedure. A draft version was reviewed by the United Parent
roject Muscular Dystrophy board (UPPMD, now World
uchenne Organization (WDO), see https://worldduchenne.
rg/). The final English version (Appendix 1) was translated
n Dutch and Italian. The questionnaire was built as an online
ersion using freely available software from SurveyMonkey®
 www.surveymonkey.com). 
.2. Participants 
In the Netherlands, a link to the electronic version of
he questionnaire was sent to all members of the Dutch
uchenne Parent Project (DPP) as part of a regular newsletter.
amilies known to the DPP as participants of a clinical trial
hat had undergone a muscle biopsy as protocol requirement
eceived a personal email containing the same link. Finally,
he participants were notified of the possibility to fill out the
uestionnaire either on paper or electronically by the local
rincipal investigator of the Leiden University Medical Center
f they had participated in this centre. In the UK, caregivers
nd patients were informed of the possibility to complete
he survey via emails from charity databases. Furthermore,
wareness of the survey was raised by social media. In
taly a personal email containing the link to the electronic
ersion of the survey was sent to caregivers and patients
nown to Parent Project onlus as participants of a clinical
rial that included a muscle biopsy. Furthermore a dedicated
nnouncement containing the electronic link to the survey was
ublished on the organization web site and on social media. 
. Results 
Responses were received from 78 children and their
aregivers from seven countries (the Netherlands, United
ingdom, Italy, United States, Canada, France and Australia)
ho reported on 150 biopsies. An overview of all
haracteristics is given in Tables S1–S6. 
Most children had participated in trials for drisapersen,
n AON designed to skip exon 51, ezutromid, a compoundcle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ 
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Fig. 1. Feeling of the children before and after the biopsy. Correlation of 
feeling of the children before and after the biopsy ( n = 75). 
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s  hat aims to increase utrophin expression, or the histone
eacetylase inhibitor givinostat. Most children had been
ounger than 10 years old when the first biopsy was taken
range: 5–16 years), and underwent two biopsies in total
range: 1–5 biopsies). Most biopsies were taken from the
iceps brachii muscle. For four patients it was unclear from
hich muscle the biopsy was taken. Their answers have been
xcluded when results are split by biopsy site. Two patients
ad biopsies taken from multiple sites. When results are split
y muscle, the answers have been taken into account for both
uscles. In 83% of the biopsies, general anaesthesia had been
sed, mainly administrated intravenously. 
.1. Short-term impact 
Around half of the children ( n = 33) indicated that they had
een nervous or scared before the biopsies, the remaining
ad felt fine or could not remember ( Fig. 1 ). There was aFig. 2. Pain caused by biopsy ( n = 76). (A) Pa
Please cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Mus
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.norrelation between the feeling of the children before and
fter the biopsies. The majority of those who felt fine before
lso felt fine afterwards, whereas more children who had been
ervous or scared before the procedure did not feel fine after
he biopsy. Examples of feelings of children who did not feel
ne were pain, tiredness and feeling emotional. In general,
hildren appeared to be less nervous before the biopsy than
heir caregivers. The largest concern of the parents/caregivers
as the anaesthesia applied during the procedure. 
In the questionnaire seven children experienced problems
ith general anaesthesia, and one with local anaesthesia.
hese problems included nausea, agitation, increased heart
ate, and difficulty waking up. One case of rhabdomyolysis
esulted in hospitalization. 
Pain after the biopsy was reported by 67 (88%) of the
esponders, whereas nine (12%) did not ( Fig. 2 A). The
ain was classified as mild to moderate by the majority
88%). Pain classification seemed slightly lower for biopsies
aken from the biceps than those obtained from leg muscles
 Fig. 2 B). The pain control given after biopsies of the biceps
as considered good or very good by 83% ( n = 48). However,
or the muscle biopsies taken from the leg, the pain treatment
ppeared less effective. The majority (89%) considered the
reatment of pain sufficient (good or very good; Table 1 ). 
Healing of the wound also had an impact on daily activities
ccording to 51% of the responders ( Fig. 3 ). Children
ndicated they had, among others, difficulties in walking,
howering, writing and were feeling uncomfortable in bed. 
.2. Long-term impact 
There was a large difference between the sizes of the scars,
anging from three to 60 mm (median 30 mm). There were no
onsistent differences in scar sizes between the biopsy sites
 Fig. 4 A). The majority of children and caregivers indicated
hat they were not or little bothered by the scars (1–2 on a
cale of 1–5) ( Fig. 4 B). For those who were bothered by theirin caused by biopsy. (B) Level of pain. 
cle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ 
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Table 1 
Treatment of pain. 
Effectiveness of pain control after biopsy split by biopsy site as considered by parents/caregivers ( n = 76). 
Level of pain 
Biceps Tibialis Gastrocnemius Quadriceps Total 
Very good 15 37% 3 19% 1 9% 0 0% 19 27% 
Good 23 56% 11 69% 9 82% 1 33% 44 62% 
Neither good nor bad 3 7% 2 13% 1 9% 1 33% 7 10% 
Bad 0 0% 0 0% 0 0% 0 0% 0 0% 
Very bad 0 0% 0 0% 0 0% 1 33% 1 1% 
Fig. 3. Impact of biopsy on daily activities ( n = 73). 
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t  scars (scores 4 and 5), the reasons varied and were mainly
aesthetic. However, four responders indicated that their scar(s)
were sometimes itchy or sensitive to touch even several years
after the biopsy. A difference was observed between feelings
of the children and the caregivers’ perception on how their
child feels; of the eight children who felt ‘bothered’, only
two of their caregivers reported similarly. Scar healing was
considered to be not satisfactory by 35%, but there was no
clear correlation between the biopsy site and how this healing
was reported ( Fig. 4 C). Caregivers’ descriptions of scars that
had not healed well, indicated that they were large, prominent,
wide, or that discoloration of the skin had occurred. Pain was
not reported as a long-term symptom. Examples of scars are
shown in Fig. 4 D-F. 
3.3. Quality of the information provided before and after the
biopsies 
Caregivers had been provided with information on the
clinical trial beforehand. Furthermore, most caregivers had a
discussion with a clinician about their concerns and had been
told about the risks of the biopsy and anaesthesia ( Fig. 5 A).
Most caregivers (80%) were satisfied with the information
given in the informed consent ( Fig. 5 B). However, some felt
that the documents did not have sufficient information, and
that the risks of the procedure and scaring were minimized.
Twenty-six percent of the caregivers indicated they had notPlease cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Mus
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.neen informed beforehand what the approximate size of the
ncision would be, whereas 7% of those who were informed
elt that the information was not accurate. 
Around three quarter of the caregivers received advice on
ow to take care of the wound, although with considerable
ariations in the instructions. Many were advised to keep
he wound dry and clean. Some others were told to apply
ntibiotic cream or avoid direct sunlight. Several also received
dvice on what to do in case of an infection (i.e. seek medical
dvice). 
Nearly all caregivers indicated that being informed about
he results of the trial was very important to them. By
ontrast, only 26% had actually received such information
 Fig. 6 A). In general, caregivers considered it important to
now the overall results of the trial as well as the biopsy
esults of their own child ( Fig. 6 B). Not receiving this
nformation resulted in feelings of frustration and irritation,
ut sometimes also anxiety, because they felt that something
ad been deliberately hidden to them. 
.4. Recommendations for future trials 
When asked whether they would participate in another
linical trial that would require one or more biopsies, 45%
f the children responded positively, while 55% answered no
r was not sure ( Fig. 7 ). Of the caregivers, 78% of caregivers
esponded positively, while 22% said no. Opinions of patients
nd caregivers often matched. Of the 34 children who would
ake part in such a trial, 33 caregivers agreed as well. Of the
8 caregivers who would allow their child to have another
iopsy, less than 10% of their children would not want to
articipate. Furthermore, the majority of the children (66%)
ould not discourage a friend from participating in this type
f trial. Children did not report a clear preference for a biopsy
ite (data not shown). Finally, caregivers found trial biopsies
ar more acceptable as part of an open-label trial than for a
lacebo-controlled trial ( Fig. 8 ). 
. Discussion 
Over the last years a significant progress has been made
n the development of therapies for DMD. Whereas five years
go only a handful of trials was ongoing, currently over
0 compounds are or have been tested in clinical trials. In
any of these trials one or more muscle biopsies are used
o determine restoration of protein expression or to showcle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ 
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Fig. 4. Scar. (A) Scar sizes per muscle: biceps ( n = 60), tibialis ( n = 32), gastrocnemius ( n = 22) and quadriceps ( n = 6). Some patients had more than one 
biopsy taken. (B) Perception of the scars by children ( n = 70) and their parents/caregivers ( n = 73). (C) Correlation between the biopsy site and scar healing 
( n = 74). (D-F) Examples of scars showing two open biopsies from the biceps (D and E) and one conchotome biopsy taken from the tibialis anterior muscle 
(F). 
Fig. 5. Information before biopsy. (A) Number of parents/caregivers who discussed their concerns ( n = 65) and/or the risks ( n = 76) with a clinician before 
the biopsy. (B) Opinion of the parents/caregivers about the clarity of the risks/benefits in the informed consent ( n = 75). 
Please cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Muscle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ 
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nmd.2019.06.004
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Fig. 6. Communication about results. (A) Number of parents/caregivers that did or did not receive the results of their child or the overall trial ( n = 76). (B) 
Importance of receiving trial results ( n = 75) and/or results of their child’s own biopsy ( n = 76). 
Fig. 7. New biopsy. Number of children ( n = 76) who would or would not 
agree with a new biopsy versus their parents/caregivers ( n = 73). 
Fig. 8. Acceptability biopsy. Acceptability of taking a biopsy for an open- 
label versus a placebo-controlled trial. 
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Please cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Mus
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nmprovement in muscle quality via histological studies. Since
uscle biopsies are invasive, we here intended to investigate
he patient and caregiver perspective on their short-term and
ong-term impacts. 
.1. The biopsy procedure 
First, the procedure itself poses risks, mainly due to the
se of anaesthesia, which requires special precautions in
MD boys compared to healthy individuals. This relates
o age and the respiratory pathology, with risks including
erioperative respiratory and cardiac complications, but also
habdomyolysis [23–25] . Our study included a relatively
oung population as most trials had been performed in
mbulant boys of 5 years and older. Nonetheless, 10% of
hildren suffered from complications, with one patient having
o be hospitalized due to severe rhabdomyolysis. Wound
nfection is considered a general, although small, risk in any
urgical procedure, but this complication was not reported. It
s important to communicate the risks well to the caregivers
hen explaining the clinical trial, and to ensure that the
naesthetic team is aware of the risks in DMD. 
Another important point is the stress the biopsy procedure
oses to the children and their family. Around halve of them
ad been anxious before the biopsy and had not felt well
fterwards, although some also said they had felt relieved
he procedure was over. This underscores the important
ole of professional educational and psychological support
or children in paediatric care, and its importance to be
onsidered in the decision to perform biopsies in clinical
rials. 
.2. Impact of the biopsy 
The muscle biopsy had short-term and long-term impacts
n patients and caregivers. On the short-term, most patients
xperienced pain, which was quite severe in some cases, whilecle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ 
md.2019.06.004
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t  n fact good pain management should avoid (most of) the
ain. Here, good communication to the caregivers is again
mportant to raise awareness of this. 
Healing of the wound can have a negative impact on daily
ife. Some boys were unable to go to school and had problems
ith, for example, showering. From the questionnaire, we
ere unable to define the extent of this period or to provide
 consistent explanation for the variability in the responses
ere. No clear relationship with the location of the biopsy
as reported. The large variability in clinical advice on wound
anagement is striking and it would be interesting to further
tudy the effect of these protocols and if these may be
ptimized. 
In our study, all patients had a visible scar, although a large
ariation in the length and healing of the scar was observed,
nd only a subset of patients and caregivers was bothered by
t. It became clear that the likelihood of a permanent scar was
ot always pointed out in the informed consent. Some consent
orms understated or even neglected the risk of scarring.
s an example one of the participants responded: “Risks of
carring was stated to be very low however, the biopsy site
cars are significant’ and ‘The consent document put the risk
f scarring, pain and suffering at approx. 20%. It should
ave been 100%.”. We feel that combining estimated risks of
ifferent symptoms does not provide the most adequate type
f information, and that information leaflets should explain
hat scarring and some level of pain will occur after any
uscle biopsy. These risks should be pointed out clearly
n the informed consent and should be communicated by
he clinician who obtains informed consent to set realistic
xpectations, but also encourage the family to seek for pain
anagement after the procedure. Despite the fact that all
atients had a scar, and this bothered a subset of parents
nd patients, the majority of parents found the benefits of
articipating in the clinical trial to outweigh the scarring,
s they indicated their willingness to be involved in future
linical trials involving a muscle biopsy. Nonetheless, scarring
s an important factor too to take into account in the medical-
thical evaluation of such trials. The questionnaire did not
nclude questions if, for example, the location of biopsies
rom the biceps was chosen to minimize visibility or if
reatment with plastic surgery had been offered to patients
nywhere in the follow-up. Despite these limitations, we feel
hat more attention could be paid on how to minimize the
osmetic impact of the scar. 
.3. Informed consent 
For many participants understanding of the informed
onsent is problematic. The consent forms tend to be long,
nd contain complex medical and legal language. This
otentially results in parents not reading or understanding
he whole informed consent documents or missing important
oints. Possibilities to improve the informed consent are
o add a simple extract with the main points or use a
ideo format. In addition, sufficient time should be taken toPlease cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Mus
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.niscuss the procedure, consequences and expectations of the
articipants. 
.4. Role of biopsies in drug research 
Biopsies currently play an important role in therapy
evelopment for DMD. Early phase clinical trials often
re open-label and biopsies are required to show proof-of-
echanism of test compounds or to find the optimal dose.
s such the biopsy analysis is used as a pharmacodynamics
iomarker [26] . However, in later phase clinical trials, a
lacebo group is added and the focus is on showing that
onger term treatment with a compound is safe and leads to
linically meaningful effects, in DMD this would be a slower
isease progression. 
Drug approval is generally not based on biomarker analysis
ut on functional effects. The approval of eteplirsen by
he FDA exceptionally was based on dystrophin analysis
n biopsies. However, this approval is conditional. FDA
equested that Sarepta provides additional data to confirm
unctional effects of the drug by 2021. If Sarepta fails
o provide the requested confirmatory data, the eteplirsen
pproval will be revoked. By contrast, the European
edicines Agency (EMA) did not approve eteplirsen based
n the same data, since functional data was lacking [27] .
evertheless this position of FDA on dystrophin as a
urrogate biomarker, which has a likely possibility to predict
linical benefit, has set a precedent for several other
ompanies involved in developing other related compounds. 
We queried the parents about the acceptance of muscle
iopsies in clinical trials. Parents indicated they considered
t more justifiable to obtain a biopsy in an open-label trial,
here it is certain their child is treated with the active
ompound, than in a trial in which the child may be receiving
lacebo. In the latter case, it was more often seen as
ndesirable to perform such an invasive procedure, more so
ecause the main goal of a placebo-controlled trial is to show
unctional benefits of the treatments. In fact, confirmation of
rug action should already have been established in early
hase trials and therefore should not be needed in follow-up
ivotal trials in larger patients groups. 
.5. Communication of trial results 
Another important aspect for increasing the acceptability
f biopsies is the communication about the results of the
rial. In many cases parents did not receive such results.
rom our questionnaire it became clear that most caregivers
ound it very important to have the results of the trial both
n general and of their own son in particular. Although it is
ppreciated that, especially in small phase 1 and 2 trials, such
ndividual information can be difficult to interpret, careful
ommunication prior to inclusion in the trial is warranted to
et realistic expectations about what information they will,
nd what information they will not receive. In addition, we
ecommend companies to send out regular newsletters to the
rial centres/patients organisations participating in the trial, socle biopsies in clinical trials for Duchenne muscular dystrophy – Patients’ 
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 they can update their patients on the progress of the trial.
Caregivers prefer to receive regular updates on the status of
the trial and the biopsy analysis so they know they have not
missed information. 
4.6. Future 
Considering the invasiveness of the procedure and the
usefulness of the results in the approval process, there is a
need for less invasive methods to determine efficacy of study
drugs. There are studies showing that dystrophin restoration
can be measured in smooth muscle layers of the skin [28,29] .
As such in the future it may be possible to take skin biopsies
rather than muscle biopsies. However, the disadvantage of
this approach is that it is possible that the distribution of
the therapeutic compound varies between skin and skeletal
muscle, which could result in both false positive and false
negative conclusions. 
Currently, open biopsies are used in most clinical trials.
Since the techniques to quantify dystrophin are improving
[30] , it may be possible to use needle biopsies in the
future that obtain smaller amounts of muscle tissue and
induce smaller scars. In the immediate future however, it is
anticipated that open biopsies are unavoidable in early phase
clinical trials for DMD. Although this questionnaire does not
allow a direct comparison, biopsies taken from the biceps may
be better tolerated than those obtained from other muscles,
causing less pain, less impact on daily activities, and better
healing of the scar. It should, however, be taken into account
that more patients who underwent a biceps biopsy received
general instead of local anaesthesia. This may have influenced
the level of pain. Furthermore, the low number of patients in
the study that received a biopsy from another muscle than
the biceps, prevents definite conclusions. Standardising the
location, techniques and processing of the tissue, would also
be essential for comparison of results between trials. 
4.7. Limitations to our study 
There are several limitations to our study. Firstly, the
study was performed retrospectively. For some participants
the biopsy was taken ten years ago, which may make it hard
to remember the circumstances at that time. Secondly, some
patients have had more than one biopsy. Even though the
questionnaire was aimed at the first biopsy, it may have been
difficult to separate the feelings and effects of the different
biopsies. In addition, the acceptance of further biopsies may
also change by the usefulness and results obtained from
previous biopsies. 
The study was performed in several countries. Thereby
responses may be influenced by cultural differences and
hampers the uniform interpretation of the answers. Only in
the Netherlands, the coverage was around 100%, whereas in
other countries it was (much) lower, causing a possible bias.
Finally, some of the subgroups were very small. Therefore
it was not possible to perform statistical analysis. Moreover
it is difficult to capture individual variation in statistics andPlease cite this article as: I.E.C. Verhaart, A. Johnson and S. Thakrar et al., Mus
and caregivers’ perspective, Neuromuscular Disorders, https:// doi.org/ 10.1016/ j.nhere were several open questions, leaving room for multiple
nterpretations. 
. Future recommendations 
Based on our study we propose several recommendations
or future studies. Firstly, sponsors should be very careful
hen considering to include one or more biopsies in their
linical trial. For early phase trials a biopsy to confirm
echanism of action of a drug may be unavoidable, while for
ater phase placebo-controlled trials biopsies are considered
nethical by part of the caregivers. 
Secondly, optimal communication is crucial to explain
o caregiver and patients what to expect. Expectation
anagement is crucial. Caregivers need to understand
bout the risks of the biopsy (anaesthesia-related) and
he consequences (scarring). Sponsors should also think
head of time on which information (aggregated and
ndividual) to communicate to the participants and how to
nform participants regularly on updates. Clinicians need to
ommunicate to caregivers that generally the pain can be
anaged well after the biopsy and to seek medical advice
n case patients are in moderate or severe pain. 
Thirdly, aesthetic aspects of the scars could benefit from
ore thorough selection of the location of the biopsy and the
onsultation of cosmetic surgeons in the longer follow-up. 
Finally, caregivers and patients are keen that the biopsy is
sed optimally. Ideally the informed consent should allow to
hare data with others to do research or additional analysis
hen the clinical trial-related analyses have been completed. 
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